EP Patent

EP2120578B1 — Kinase inhibitor compounds

Assigned to Tyrogenex Inc · Expires 2014-11-19 · 11y expired

What this patent protects

Patent listed against ensartinib-hydrochloride.

Drugs covered by this patent

ensartinib-hydrochloride (ENSARTINIB HYDROCHLORIDE)

Patent Metadata

Patent number: EP2120578B1
Jurisdiction: EP
Classification: —
Expires: 2014-11-19
Drug substance claim: No
Drug product claim: No
Assignee: Tyrogenex Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.